J. Studios
- Valneva Se (Nasdak:ValinIt reduces its sales and revenues in 2025 in 2025 as a result of August decision from the United States of America cancellation Marketing license its vaccine in Chikungunya Ixchiq due to safety concerns.
- Product sales are now expected for 155 million euros-170 million euros, below
https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2158301125/image_2158301125.jpg?io=getty-c-w750
Source link